Collegium Pharmaceutical, Inc. (COLL) financial statements and ratios from SEC XBRL: revenue $780.57M (latest fiscal year), net margin 8.1%, revenue growth 23.6% YoY, P/E 19.4. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $780.57M |
| Net Margin | 8.1% |
| Revenue Growth (YoY) | 23.6% |
| EPS Growth (YoY) | -7.5% |
| FCF Growth (YoY) | 61.1% |
| P/E Ratio | 19.4 |
| EV / EBITDA | 5.6 |
| Price / Book | 2.83 |
| Price / Sales | 1.11 |
| FCF Yield | 50.6% |
| Altman Z-Score | 1.31 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
COLL overview · COLL earnings · COLL KPIs · COLL documents · COLL ownership · COLL peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.